【New Product】Beilu Pharmaceutical's Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets Approved

Recently, Beilu Pharmaceutical received the "Drug Registration Certificate" for Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets with a specification of 25mg (calculated as C₁₉H₂₀FNO₃) from the National Medical Products Administration.

"Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets" are used for the treatment of adult depression, classified as a Category B drug in the national medical insurance directory, and was developed by GlaxoSmithKline. According to WHO data, over 350 million people worldwide suffer from depression, with a patient growth rate of about 18% over the past decade, meaning that 5% of adults worldwide suffer from depression each year. Based on the "2022 National Depression Blue Book," there are approximately 95 million affected individuals in our country, constituting a large population. Against the backdrop of a rising incidence of depression and increased patient awareness in our country, the market demand for this product is expected to grow further in the future.

The Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets, approved as a Class 4 chemical drug, are deemed to have passed the evaluation of quality and efficacy consistency for generic drugs, which will further enrich Beilu Pharmaceutical 's portfolio of psycho-neurological products and help enhance the market competitiveness of the company's products. The company will actively carry out various preparations for the new product launch and strive to bring the product to the market as soon as possible.